Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

The Role of Thrombotic Events in Disease Advancement, Cancer Incidence, and Mortality Among Patients with Essential Thrombocythemia and Polycythemia Vera

  • By

  • A. Angona

  • B. Cuevas

  • M. Pérez-Encinas

  • F. Ferrer-Marin

  • A. Senín

  • E. Arellano-Rodrigo

  • J. C. Hernández-Boluda

  • M. I. Mata Vázquez

  • G. Caballero-Navarro

  • M. T. Gómez-Casares

  • E. Magro

  • G. Carreño-Tarragona

  • M. A. Cortés-Vázquez

  • R. Pérez López

  • V. García-Gutiérrez

  • M. S. Noya-Pereira

  • J. M. Alonso-Dominguez

  • C. Sierra- Aisa

  • L. Fox

  • C. García Hernández

  • J. M. Guerra

  • E. Cerezo

  • M. Gasior

  • M. Santaliestra

  • I. Díez

  • M. V. Cuevas

  • L. Sanz

  • I. Pastor

  • R. Stuckey

  • P. Vélez

  • C. Auría-Caballero

  • A. Alvarez-Larrán

  • May 7, 2026

Share

Clinical Scorecard: The Role of Thrombotic Events in Disease Advancement, Cancer Incidence, and Mortality Among Patients with Essential Thrombocythemia and Polycythemia Vera

At a Glance

CategoryDetail
Condition
Key MechanismsThrombotic events (arterial and venous) impact survival, disease progression, and second cancer incidence, with arterial thrombosis showing a more pronounced effect.
Target Population
Care Setting

Key Highlights

  • Thrombotic events significantly lower survival rates in ET and PV patients.
  • Arterial thrombosis (AT) is associated with increased mortality risk.
  • No significant association found between venous thrombosis (VT) and survival; specific study data should be included.
  • JAK2V617F mutation correlates with higher risk of second cancers.
  • AT may indicate a more aggressive disease biology.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular follow-up for thrombotic events and disease progression every 3-6 months.
      • Assess for second cancers in patients with a history of AT.

      Risks

        Patient & Prescribing Data

        Management should prioritize thrombotic event prevention, including options like low-dose aspirin, and monitor for disease progression.

        Clinical Best Practices

        • Implement strategies to reduce thrombotic risk in MPN patients.
        • Educate patients on recognizing symptoms of thrombosis and lifestyle modifications.
        • Utilize genetic testing to inform treatment decisions.

        References

        Original Source(s)

        Impact of thrombosis on disease progression, cancer and mortality in patients with essential thrombocythemia and polycythemia vera

        • by A. Angona, B. Cuevas, M. Pérez-Encinas, F. Ferrer-Marin, A. Senín, E. Arellano-Rodrigo, J. C. Hernández-Boluda, M. I. Mata Vázquez, G. Caballero-Navarro, M. T. Gómez-Casares, E. Magro, G. Carreño-Tarragona, M. A. Cortés-Vázquez, R. Pérez López, V. García-Gutiérrez, M. S. Noya-Pereira, J. M. Alonso-Dominguez, C. Sierra- Aisa, L. Fox, C. García Hernández, J. M. Guerra, E. Cerezo, M. Gasior, M. Santaliestra, I. Díez, M. V. Cuevas, L. Sanz, I. Pastor, R. Stuckey, P. Vélez, C. Auría-Caballero, A. Alvarez-Larrán

        • May 7, 2026

        Related Content

        AI-Designed Binder Improves CAR T Cell Activity in Mice

        Researchers screened 1,758 de novo protein binders and identified design features that influence CAR T cell activation, specificity, and tumor control

        • September 15, 2026

        • 3 min
        Clinician Counseling and Weight Loss Attempts Among Survivors of Obesity-Associated Cancers

        Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer

        The goal of this clinical trial is to learn if Adaptive Radiation Therapy (ART) is safe and effective in treating patients with locally advanced pancreatic cancer.

        • by

        • September 4, 2026

        • 4 min